Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;15(1):520-526.
doi: 10.3892/etm.2017.5414. Epub 2017 Nov 1.

The effect of hydroxy safflower yellow A on coronary heart disease through Bcl-2/Bax and PPAR-γ

Dayan Zhou  1 , Zongjie Qu  1 , Hao Wang  1 , Yong Su  1 , Yazhu Wang  1 , Weiwei Zhang  1 , Zhe Wang  1 , Qiang Xu  1
Affiliations

The effect of hydroxy safflower yellow A on coronary heart disease through Bcl-2/Bax and PPAR-γ

Dayan Zhou et al. Exp Ther Med. 2018 Jan.

Abstract

The aim of the present study was to investigate the effect of hydroxy safflower yellow A (HSYA) on coronary heart disease through assessing the expression of B-cell lymphoma 2 (Bcl-2)/Bcl-2-like protein 4 (Bax) and peroxisome proliferator-activated receptor (PPAR)-γ. Coronary heart disease was induced in male Bama miniature swines via thoracoscope to serve as an animal model. Coronary heart disease swine were lavaged with 20 or 40 mg/kg HSYA. The mRNA levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-10, cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) were detected using reverse transcription-quantitative polymerase chain reaction. The protein expression of Bcl-2, Bax, PPAR-γ, phosphorylation of Janus kinase (JAK)2 and phosphorylation of signal transducer and activator of transcription (STAT)3 were detected using western blot analysis. Treatment with HSYA significantly suppressed the mRNA levels of IL-1β (P<0.01), IL-6 (P<0.01), TNF-α (P<0.01), COX-2 (P<0.01) and iNOS (P<0.01), and significantly increased IL-10 mRNA level in the coronary heart disease model (P<0.01). Furthermore, HSYA treatment significantly decreased the Bcl-2/Bax ratio (P<0.01) in the coronary heart disease model group, and enhanced the phosphorylation of JAK2/STAT3 pathway (P<0.01). However, HSYA had no significant effect on the expression of PPAR-γ protein. The results of the present study suggest that HSYA is able to weaken coronary heart disease via inflammation, Bcl-2/Bax and the PPAR-γ signaling pathway.

Keywords: B-cell lymphoma 2; B-cell lymphoma-like protein 4; coronary heart disease; hydroxy safflower yellow A; inflammation; peroxisome proliferator-activated receptor-γ.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Chemical structure of hydroxy safflower yellow A.
Figure 2.
Figure 2.
Effect of HSYA on LVIDs and LVEF in coronary heart disease model. The effect of HSYA on (A) LVIDs and (B) LVEF in a coronary heart disease model. **P<0.01 vs. sham; ##P<0.01 vs. model. HSYA, hydroxy safflower yellow A; LVEF, left ventricular ejection fraction; LVID, left ventricular systolic internal diameter; sham, sham group; model, coronary heart disease model group; HSYA-L, low dose HSYA group; HSYA-H, high dose HSYA group.
Figure 3.
Figure 3.
Effect of HSYA on biochemical composition in coronary heart disease model. The effect of HSYA on (A) Scr, (B) BUN and (C) urine in a coronary heart disease model. **P<0.01 vs. sham; ##P<0.01 vs. model. HSYA, hydroxy safflower yellow A; Scr, plasma creatine; BUN, blood urea nitrogen; sham, sham group; model, coronary heart disease model group; HSYA-L, low dose HSYA group; HSYA-H, high dose HSYA group.
Figure 4.
Figure 4.
Effect of HSYA on the mRNA levels of IL-1β, IL-6, IL-10 and TNF-α in coronary heart disease model. The effect of HSYA on the mRNA levels of (A) IL-1β, (B) IL-6, (C) TNF-α and (D) IL-10 in a coronary heart disease model. **P<0.01 vs. sham; ##P<0.01 vs. model. HSYA, hydroxy safflower yellow A; IL, interleukin; TNF, tumor necrosis factor; sham, sham group; model, coronary heart disease model group; HSYA-L, low dose HSYA group; HSYA-H, high dose HSYA group.
Figure 5.
Figure 5.
Effect of HSYA on the mRNA levels of COX-2 in a coronary heart disease model. **P<0.01 vs. sham; ##P<0.01 vs. model. HSYA, hydroxy safflower yellow A; COX, cyclooxygenase; sham, sham group; Model, coronary heart disease model group; HSYA-L, low dose HSYA group; HSYA-H, high dose HSYA group.
Figure 6.
Figure 6.
Effect of HSYA on the mRNA levels of iNOS in a coronary heart disease model. **P<0.01 vs. sham; ##P<0.01 vs. model. HSYA, hydroxy safflower yellow A; iNOS, inducible nitric oxide synthase; sham, sham group; model, coronary heart disease model group; HSYA-L, low dose HSYA group; HSYA-H, high dose HSYA group.
Figure 7.
Figure 7.
Effect of HSYA on the Bcl-2/Bax ratio and PPAR-γ in coronary heart disease model. The effect of HSYA on the Bcl-2/Bax and PPAR-γ protein expression by (A) western blotting assays and statistical analysis of (B) Bcl-2/Bax and (C) PPAR-γ protein expression in coronary heart disease model. **P<0.01 vs. sham; ##P<0.01 vs. model. HSYA, hydroxy safflower yellow A; Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-like protein 4; Sham, sham group; Model, coronary heart disease model group; HSYA-L, low dose HSYA group; HSYA-H, high dose HSYA group.
Figure 8.
Figure 8.
Effect of HSYA on the phosphorylation of JAK2 and STAT3 protein expression in coronary heart disease model. (A) Western blotting and statistical analysis of (B) p-JAK2 and (C) p-STAT3 protein expression in the coronary heart disease model. **P<0.01 vs. sham; ##P<0.01 vs. model. HSYA, hydroxyl safflower yellow A; JAK, Janus kinase; STAT, signal transducer and activator of transcription; p-, phosphorylated; sham, sham group; model, coronary heart disease model group; HSYA-L, low dose HSYA group; HSYA-H, high dose HSYA group.
See this image and copyright information in PMC

References

    1. Berndt N, Bolman C, Froelicher ES, Mudde A, Candel M, de Vries H, Lechner L. Effectiveness of a telephone delivered and a face-to-face delivered counseling intervention for smoking cessation in patients with coronary heart disease: A 6-month follow-up. J Behav Med. 2014;37:709–724. - PubMed
    1. Moser DK, McKinley S, Riegel B, Doering LV, Meischke H, Pelter M, Davidson P, Baker H, Dracup K. The impact on anxiety and perceived control of a short one-on-one nursing intervention designed to decrease treatment seeking delay in people with coronary heart disease. Eur J Cardiovasc Nurs. 2012;11:160–167. doi: 10.1016/j.ejcnurse.2010.11.003. - DOI - PMC - PubMed
    1. Grunwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, et al. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer. 2012;48:324–332. doi: 10.1016/j.ejca.2011.06.054. - DOI - PubMed
    1. Derosa G, Bonaventura A, Bianchi L, Romano D, D'Angelo A, Fogari E, Maffioli P. A randomized, placebo-controlled study on the effects of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters. J Biol Regul Homeost Agents. 2014;28:317–324. - PubMed
    1. Kuravi SJ, McGettrick HM, Satchell SC, Saleem MA, Harper L, Williams JM, Rainger GE, Savage CO. Podocytes regulate neutrophil recruitment by glomerular endothelial cells via IL-6-mediated crosstalk. J Immunol. 2014;193:234–243. doi: 10.4049/jimmunol.1300229. - DOI - PMC - PubMed